Table 3.
The subgroup analysis of prognostic role of SII for PFS in OC.
| Subgroups | No. of studies | No. of patients | Effects model | HR (95%CI) | p | Heterogeneity I2 (%) Ph |
|
|---|---|---|---|---|---|---|---|
| Total | 6 | 1,546 | REM | 2.71 (1.78-4.12) | <0.001 | 65.5 | 0.013 |
| Country | |||||||
| China | 3 | 763 | REM | 3.41 (1.85-6.27) | <0.001 | 64.0 | 0.062 |
| Italy | 2 | 734 | FEM | 1.61 (1.04-2.48) | 0.032 | 33.0 | 0.022 |
| India | 1 | 49 | – | 3.70 (2.18-6.29) | <0.001 | – | – |
| Sample size | |||||||
| <200 | 3 | 259 | FEM | 2.90 (2.12-3.98) | <0.001 | 0 | 0.535 |
| ≥200 | 3 | 1,287 | REM | 2.63 (1.00-6.93) | 0.050 | 83.6 | 0.002 |
| Treatment | |||||||
| Chemotherapy | 3 | 532 | REM | 2.29 (1.24-4.21) | 0.008 | 72.4 | 0.027 |
| Surgery | 2 | 912 | REM | 3.93 (1.14-13.56) | 0.030 | 82.3 | 0.017 |
| Surgery + chemotherapy | 1 | 102 | – | 2.59 (1.47-4.55) | 0.001 | – | – |
| Study center | |||||||
| Single center | 5 | 1,171 | FEM | 3.05 (2.33-3.98) | <0.001 | 44.7 | 0.124 |
| Multicenter | 1 | 375 | – | 1.25 (0.69-2.26) | 0.459 | – | – |
| Cut-off value | |||||||
| <720 | 3 | 710 | REM | 3.85 (2.20-6.73) | <0.001 | 59.1 | 0.087 |
| ≥720 | 3 | 836 | FEM | 1.91 (1.36-2.70) | <0.001 | 37.6 | 0.201 |
PFS, progression-free survival; SII, systemic immune-inflammation index; OC, ovarian cancer; FEM, fixed-effects model; REM, random-effects model.
"-" means blank.